Episode 1: 2023 – How to determine commercial value in a downturn

January 2023

How can you predict how payers around the world will value new therapies when caution remains the dominant theme of 2023? Darius Lakdawalla and EntityRisk CEO Neal Masia answer that question in the webcast below. They also discuss the news from JPM 2023 and review formulas for success in a prolonged downturn.